Northern Trust’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-991,043
| Closed | -$3.01M | – | 4538 |
|
|
2024
Q4 | $3.01M | Buy |
991,043
+26,248
| +3% | +$114K | ﹤0.01% | 2796 |
|
|
2024
Q3 | $5.01M | Buy |
964,795
+98,609
| +11% | +$490K | ﹤0.01% | 2473 |
|
|
2024
Q2 | $2.23M | Buy |
866,186
+957
| +0.1% | +$3.27K | ﹤0.01% | 2845 |
|
|
2024
Q1 | $4.26M | Sell |
865,229
-22,307
| -3% | -$132K | ﹤0.01% | 2573 |
|
|
2023
Q4 | $7.8M | Buy |
887,536
+49,180
| +6% | +$403K | ﹤0.01% | 2229 |
|
|
2023
Q3 | $9.62M | Buy |
838,356
+8,582
| +1% | +$165K | ﹤0.01% | 2035 |
|
|
2023
Q2 | $21M | Buy |
829,774
+23,674
| +3% | +$737K | ﹤0.01% | 1553 |
|
|
2023
Q1 | $26M | Buy |
806,100
+12,667
| +2% | +$395K | 0.01% | 1386 |
|
|
2022
Q4 | $14.6M | Buy |
793,433
+77,784
| +11% | +$1.78M | ﹤0.01% | 1747 |
|
|
2022
Q3 | $19.3M | Buy |
715,649
+37,349
| +6% | +$758K | ﹤0.01% | 1487 |
|
|
2022
Q2 | $9.37M | Sell |
678,300
-28,316
| -4% | -$436K | ﹤0.01% | 2078 |
|
|
2022
Q1 | $13.8M | Sell |
706,616
-23,941
| -3% | -$363K | ﹤0.01% | 1934 |
|
|
2021
Q4 | $11.9M | Sell |
730,557
-7,525
| -1% | -$125K | ﹤0.01% | 2112 |
|
|
2021
Q3 | $20.6M | Sell |
738,082
-13,770
| -2% | -$393K | ﹤0.01% | 1788 |
|
|
2021
Q2 | $22.3M | Buy |
751,852
+29,989
| +4% | +$865K | ﹤0.01% | 1807 |
|
|
2021
Q1 | $20.2M | Sell |
721,863
-41,761
| -5% | -$1.16M | ﹤0.01% | 1819 |
|
|
2020
Q4 | $21.6M | Sell |
763,624
-23,304
| -3% | -$604K | ﹤0.01% | 1733 |
|
|
2020
Q3 | $19.8M | Buy |
786,928
+48,463
| +7% | +$1.27M | ﹤0.01% | 1642 |
|
|
2020
Q2 | $18M | Buy |
738,465
+77,073
| +12% | +$1.52M | ﹤0.01% | 1705 |
|
|
2020
Q1 | $9.79M | Buy |
661,392
+73,968
| +13% | +$1.53M | ﹤0.01% | 1882 |
|
|
2019
Q4 | $9.53M | Buy |
587,424
+24,494
| +4% | +$380K | ﹤0.01% | 2210 |
|
|
2019
Q3 | $7.32M | Buy |
562,930
+57,485
| +11% | +$703K | ﹤0.01% | 2336 |
|
|
2019
Q2 | $6.56M | Buy |
505,445
+6,511
| +1% | +$82.1K | ﹤0.01% | 2404 |
|
|
2019
Q1 | $7.86M | Buy |
498,934
+70,584
| +16% | +$1.22M | ﹤0.01% | 2301 |
|
|
2018
Q4 | $8.62M | Sell |
428,350
-10,519
| -2% | -$232K | ﹤0.01% | 2185 |
|
|
2018
Q3 | $10.9M | Buy |
438,869
+23,013
| +6% | +$626K | ﹤0.01% | 2210 |
|
|
2018
Q2 | $11.4M | Buy |
415,856
+76,406
| +23% | +$2.3M | ﹤0.01% | 2183 |
|
|
2018
Q1 | $10.5M | Buy |
339,450
+38,045
| +13% | +$1.22M | ﹤0.01% | 2142 |
|
|
2017
Q4 | $10.8M | Buy |
301,405
+10,455
| +4% | +$300K | ﹤0.01% | 2133 |
|
|
2017
Q3 | $8.02M | Sell |
290,950
-27,927
| -9% | -$677K | ﹤0.01% | 2334 |
|
|
2017
Q2 | $8.42M | Buy |
318,877
+52,940
| +20% | +$1.18M | ﹤0.01% | 2286 |
|
|
2017
Q1 | $5.53M | Buy |
265,937
+5,623
| +2% | +$115K | ﹤0.01% | 2499 |
|
|
2016
Q4 | $5.39M | Buy |
260,314
+8,776
| +3% | +$147K | ﹤0.01% | 2507 |
|
|
2016
Q3 | $4.08M | Buy |
251,538
+19,744
| +9% | +$287K | ﹤0.01% | 2652 |
|
|
2016
Q2 | $3.15M | Buy |
231,794
+16,939
| +8% | +$300K | ﹤0.01% | 2767 |
|
|
2016
Q1 | $3.75M | Buy |
214,855
+2,889
| +1% | +$58.8K | ﹤0.01% | 2597 |
|
|
2015
Q4 | $7.24M | Buy |
211,966
+34,658
| +20% | +$1.2M | ﹤0.01% | 2222 |
|
|
2015
Q3 | $5.28M | Buy |
177,308
+70,885
| +67% | +$2.15M | ﹤0.01% | 2405 |
|
|
2015
Q2 | $3.4M | Buy |
106,423
+4,747
| +5% | +$122K | ﹤0.01% | 2766 |
|
|
2015
Q1 | $2.11M | Buy |
101,676
+9,226
| +10% | +$159K | ﹤0.01% | 3091 |
|
|
2014
Q4 | $1.57M | Buy |
92,450
+1,471
| +2% | +$25.7K | ﹤0.01% | 3233 |
|
|
2014
Q3 | $1.76M | Buy |
90,979
+16,415
| +22% | +$428K | ﹤0.01% | 3182 |
|
|
2014
Q2 | $2.54M | Buy |
74,564
+45,973
| +161% | +$1.44M | ﹤0.01% | 2941 |
|
|
2014
Q1 | $901K | Buy |
+28,591
| New | +$893K | ﹤0.01% | 3422 |
|
Other funds holding RVNC
Northern Trust's RVNC Position: Q1 2025 in Review
Northern Trust sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 991,043 shares — an estimated $3.01M sold.
Northern Trust first reported a position in RVNC in Q1 2014 and held it in 44 quarters. The position peaked at $26M in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Northern Trust reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Northern Trust sold 991,043 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $3.01M.
- Northern Trust first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 44 quarters.
- Northern Trust's Revance Therapeutics, Inc. position peaked at $26M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Northern Trust's 13F filing for Q1 2025, filed 13 May 2025.